Radiotherapy and immune checkpoint blockade: Potential interactions and future directions

Trends in Molecular Medicine

Volumn 21, Issue 8, 2015, Pages 463-465

  Binder, David C ^a   Fu, Yang Xin ^a,b   Weichselbaum, Ralph R ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Immunotherapy; Radiation

Indexed keywords

BLOCKING ANTIBODY; CANCER ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMOSENSITIZATION; DENDRITIC CELL; HUMAN; IMMUNOSTIMULATION; MACROPHAGE; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SURVIVAL TIME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; FEMALE; IMMUNOLOGY; RADIATION RESPONSE; T LYMPHOCYTE;

ANIMALIA;

ANIMALS; ANTIGENS, CD274; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; FEMALE; HUMANS; MELANOMA; T-LYMPHOCYTES;

EID: 84938546841     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.05.007     Document Type: Short Survey

References (10)

1. Postow, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
2. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
3. Tumeh, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
4. + T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
5. Burnette B., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
6. Deng L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
7. Demaria S., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005, 11:728-734.
8. Twyman-Saint Victor C.A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
9. Deng L., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014, 124:687-695.
10. Restifo N.P., et al. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.